Contribute Try STAT+ Today

Good morning, everyone, and welcome to another working week. We hope the weekend respite was relaxing and invigorating because — yes, you guessed it — the inevitable routine of meetings, deadlines, Skype calls, and endless messaging has predictably returned. There is just no stopping it, though. So rather than resist, let a fresh cup of stimulation ease the pain. Our choice today is butter pecan, for those who like to experiment. Meanwhile, here are some tidbits to push you along. Hope all goes well and do stay in touch …

Although the Sackler family rejected a demand they give up $4.5 billion of their personal wealth to settle opioid claims against Purdue Pharma, the company says talks are continuing, the Associated Press reports. A bankruptcy filing seemed imminent after two state attorneys general negotiating with the company said talks with members of the Sackler family reached an impasse over the weekend, according to NPR. But if a bankruptcy filing occurs, it could change the litigation landscape instantly.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.